[Form 4] PTC Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

PTC Therapeutics insider transactions on 09/08/2025: Eric Pauwels, the company's Chief Business Officer and a director, executed a series of option exercises and contemporaneous sales under a Rule 10b5-1 plan adopted June 4, 2025. The filings show multiple option exercises at strike prices between $11.23 and $30.86 that resulted in acquisitions totaling 59,060 shares across several tranches. Simultaneously, Pauwels sold a total of 59,060 shares in multiple trades at weighted average sale prices in the mid-$56 range, reducing his reported beneficial ownership to 72,912 shares. Certain acquired shares include 272 shares from the employee stock purchase plan.

Insights

Securities Analyst

TL;DR: Insider exercised options and sold the resulting shares under a pre-established 10b5-1 plan, leaving meaningful retained ownership.

The filings indicate synchronized exercises and sales executed pursuant to a 10b5-1 plan, which typically aims to avoid timing-based trading claims. The activity increased reported gross acquisitions via exercises across multiple strikes ($11.23–$30.86) and generated proceeds via sales at weighted average prices around $56.6–$56.9. Net effect: reported beneficial ownership declined to 72,912 shares. For investors, this is a liquidity/harvesting event rather than an unplanned divestiture; materiality depends on context of total outstanding shares which is not provided in this filing.

Corporate Governance Expert

TL;DR: Transactions were executed under a documented 10b5-1 plan and are disclosed with weighted-average prices and exercise details.

The report appropriately discloses exercise dates, strike prices, resulting share counts, and weighted-average sale prices. The filer includes explanatory notes about the 10b5-1 plan adoption date and aggregation of multi-trade sale prices. Signature by an attorney-in-fact is included. From a governance and disclosure perspective, the form meets standard SEC Form 4 transparency expectations; it does not provide any forward-looking information or rationale beyond compliance documentation.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pauwels Eric

(Last) (First) (Middle)

C/O PTC THERAPEUTICS, INC.

500 WARREN CORPORATE CENTER DRIVE

(Street)

WARREN NJ 07059

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PTC THERAPEUTICS, INC. [ PTCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF BUSINESS OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
09/08/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/08/2025		M(1)		16,698	A	$30.86	89,610(2)	D
Common Stock	09/08/2025		S(1)		16,698	D	$56.94(3)	72,912	D
Common Stock	09/08/2025		M(1)		6,017	A	$11.23	78,929	D
Common Stock	09/08/2025		S(1)		6,017	D	$56.91(4)	72,912	D
Common Stock	09/08/2025		M(1)		8,528	A	$18.01	81,440	D
Common Stock	09/08/2025		S(1)		8,528	D	$56.92(5)	72,912	D
Common Stock	09/08/2025		M(1)		3,713	A	$30.86	76,625	D
Common Stock	09/08/2025		S(1)		3,713	D	$56.92(6)	72,912	D
Common Stock	09/08/2025		M(1)		2,406	A	$11.23	75,318	D
Common Stock	09/08/2025		S(1)		2,406	D	$56.92(7)	72,912	D
Common Stock	09/08/2025		M(1)		1,238	A	$11.32	74,150	D
Common Stock	09/08/2025		S(1)		1,238	D	$56.85(8)	72,912	D
Common Stock	09/08/2025		M(1)		1,250	A	$11.32	74,162	D
Common Stock	09/08/2025		S(1)		1,250	D	$56.86(9)	72,912	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$30.86	09/08/2025		M(1)			16,698	(10)	01/03/2026	Common Stock	16,698	$0	3,713	D
Stock Option (Right to Buy)	$11.23	09/08/2025		M(1)			6,017	(10)	01/02/2027	Common Stock	6,017	$0	2,406	D
Stock Option (Right to Buy)	$18.01	09/08/2025		M(1)			8,528	(10)	01/02/2028	Common Stock	8,528	$0	0	D
Stock Option (Right to Buy)	$30.86	09/08/2025		M(1)			3,713	(10)	01/03/2026	Common Stock	3,713	$0	0	D
Stock Option (Right to Buy)	$11.23	09/08/2025		M(1)			2,406	(10)	01/02/2027	Common Stock	2,406	$0	0	D
Stock Option (Right to Buy)	$11.32	09/08/2025		M(1)			1,238	(10)	02/24/2026	Common Stock	1,238	$0	1,250	D
Stock Option (Right to Buy)	$11.32	09/08/2025		M(1)			1,250	(10)	02/24/2026	Common Stock	1,250	$0	0	D

Explanation of Responses:

1. This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on June 4, 2025.

2. Includes 272 shares of common stock acquired under the Issuer's employee stock purchase plan for the period ended June 30, 2025.

3. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $56.59 to $57.41 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

4. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $56.50 to $57.42 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

5. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $56.50 to $57.38 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

6. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $56.60 to $57.45 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

7. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $56.57 to $57.45 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

8. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $56.50 to $57.14 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

9. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $56.50 to $57.10 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

10. Currently exercisable.

	/s/ Avraham S. Adler, Attorney-in-Fact	09/09/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.